OrlandiA., Bochaton-PiallatM.L., GabbianiG., SpagnoliL.G.Aging, smooth muscle cells and vascular pathobiology: implications for atherosclerosis.Atherosclerosis2006; 188: 221–30.
6.
YildizO.Vascular smooth muscle and endothelial functions in aging.Ann N Y Acad Sci2007; 1100: 353–60.
7.
GriendlingK.K., MinieriC.A., OllerenshawJ.D., AlexanderR.W.Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells.Circ Res1994; 74: 1141–8.
8.
TaddeiS., VirdisA., MatteiP., NataliA., FerranniniE., SalvettiA.Effect of insulin on acetylcholine-induced vasodilation in normotensive subjects and patients with essential hypertension.Circulation1995; 92: 2911–8.
9.
Armas-PadillaM.C., Armas-HernandezM.J., Sosa-CanacheB.Nitric oxide and malondialdehyde in human hypertension.Am J Ther2007; 14: 172–6.
10.
KuzkayaN., WeismannN., HarrisonD.G., DikalovS.Interactions of peroxynitrite, tetrahydrobiopterin, ascorbic acid, and thiols: implications for uncoupling endothelial nitric-oxide synthase.J Biol Chem2003; 278: 22546–54.
11.
DrabM., VerkadeP., ElgerM.Loss of caveolae, vascular dysfunction and pulmonary defects in caveolin-1 gene-disrupted mice.Science2001; 293: 2449–52.
12.
De VrieseA.S., VerbeurenT.J., van de VoordeJ., LameireN.H., VanhoutteP.M.Endothelial dysfunction in diabetes.Br J Pharmacol2000; 130: 963–74.
13.
BaronA.D., SteinbergH.O., ChakerH., LeamingR., JohnsonA., BrechtelG.Insulin- mediated skeletal muscle vasodilation contributes to both insulin sensitivity and responsiveness in lean humans.J Clin Invest1995; 96: 786–92.
14.
FreemanD.J., NorrieJ., SattarN.Pravastatin and the development of the diabetes mellitus: evidence for a protective treatment effect in the West Scotland Coronary Prevention Study.Circulation2001; 103: 357–62.
15.
YusufS., SleightP., PogueJ., BoschJ., DaviesR., DagenaisG.Effects of an angiotensin- converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators.N Engl J Med2000; 342: 145–53.
16.
KaufmannP.A., Gnecchi-RusconeT, CamiciP.G.Coronary heart disease in smokers: vitamin C restores coronary microcirculatory function.Circulation2000; 102: 1233–8.
StangerO., WegerM.Interactions of homocysteine, nitric oxide, folate and radicals in the progressively damaged endothelium.Clin Chem Lab Med2003; 41: 1444–54.
19.
UngvariZ., CsiszarA., EdwardsJ.G.Increased super-oxide production in coronary arteries in hyperhomocysteinemia. Role of tumor necrosis factor-alpha, NAD(P)H oxidase, and inducible nitric oxide synthase.Arterioscler Thromb Vasc Biol2003; 23: 418–23.
20.
BögerR.H., LentzS.R., Bode-BögerS.M., KnappH.R., HaynesW.G.Elevation of asymmetrical dimethylarginine may mediate endothelial dysfunction during experimental hyperhomocyst(e)inemia in humans.Clin Sci (Lond)2001; 100: 161–7.
21.
StühlingerM.C., TsaoP.S., HerJ.H., KimotoM., BalintR.F., CookeJ.P.Homocysteine impairs the nitric oxide synthase pathway. Role of asymmetrical dimethylarginine.Circulation2001; 104: 2569–75.
LeiperJ., VallanceP.Biological significance of endogenous methylarginines that inhibit nitric oxide synthases.Cardiovasc Res1999; 43: 542–8.
24.
BogerR.H., Bode-BogerS.M., SzubaA.Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia.Circulation1998; 98: 1842–7.
25.
SurdackiA., NowichiM., SandmannJ.Reduced urinary excretion of nitric oxide metabolites and increased plasma levels of asymmetric dimethylarginine in men with essential hypertension.J Cardiovasc Pharmacol1999; 33: 652–8.
26.
AbbasiF., AsagmiT., CookeJ.P.Plasma concentrations of asymmetric dimethylarginine are increased in patients with type 2 diabetes mellitus.Am J Cardiol2001; 88: 1201–3.
27.
ZoccaliC., Bode-BogerS.M., MallamaciF.Plasma concentrations of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study.Lancet2001; 358: 2113–7.
28.
ValkonenV.P., PaivaH., SalonenJ.T.Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine.Lancet2001; 358: 2127–8.
29.
LuT.M., DingY.A., LinS.J., LeeW.S., TaiH.C.Plasma levels of asymmetrical dimethylarginine and adverse cardiovascular events after percutaneous coronary intervention.Eur Heart J2003; 24: 1912–9.
30.
KremplT.K., MaasR., SydowK., MeinertzT., BogerR.H., KahlerJ.Elevation of asymmetric dimethylarginine in patients with unstable angina and recurrent cardiovascular events.Eur Heart J2005; 26: 1846–51.
31.
ZhangW.Z., VenardosK., Chin-DustingJ., KayeD.M.Adverse effects of cigarette smoke on NO bioavailability: role of arginine metabolism and oxidative stress.Hypertension2006; 48: 278–85.
32.
MichaudS.E., DussaultS., GroleauJ., HaddadP., RivardA.Cigarette smoke exposure impairs VEGF-induced endothelial cell migration: role of NO and reactive oxygen species.J Mol Cell Cardiol2006; 41: 275–84.
33.
DavidsonS.M., DuchenM.R.Endothelial mitochondria: contributing to vascular function and disease.Circ Res2007; 100: 1128–41.
34.
BelgeC., MassionP.B., PelatM., BalligandJ.L.Nitric oxide and the heart: update on new paradigms.Ann N Y Acad Sci2005; 1047: 173–82.
GealekmanO., AbbasiZ., RubinsteinI., WinaverJ., BinahO.Role of myocardial inducible nitric oxide synthase in contractile dysfunction and beta-adrenergic hyporesponsiveness in rats with experimental volume-overload heart failure.Circulation2002; 105: 236–43.
37.
SaitoT., HuF., TayaraL., FahasL., ShennibH., GiaidA.Inhibition of NOS II prevents cardiac dysfunction in myocardial infarction and congestive heart failure.Am J Physiol Heart Circ Physiol2002; 283: H339–45.
38.
CotterG., KaluskiE., BlattA.L-NMMA (a nitric oxide synthase inhibitor) is effective in the treatment of cardiogenic shock.Circulation2000; 101: 1358–61.
39.
IgnarroL.J., BalestrieriM.L., NapoliC.Nutrition, physical activity, and cardiovascular disease: an update.Cardiovasc Res2007; 73: 326–40.
40.
CalderP.C.n-3 Fatty acids and cardiovascular disease: evidence explained and mechanisms explored.Clin Sci (Lond)2004; 107: 1–11.
41.
KabatA., DheinS.L-arginine supplementation prevents the development of endothelial dysfunction in hyperglycaemia pharmacology.Pharmacology2006; 76: 185–91.
42.
LermanA., BurnettJ.C., HiganoS.T.L-Arginine supplementation prevents the development of endothelial dysfunction in hyperglycaemia.Pharmacology2006; 76: 185–95.
43.
KinlayS., BehrendtD., FangJ.C.Long term effect of combined vitamins E and C on coronary and peripheral endothelial function.J Am Coll Cardiol2004; 43: 629–34.
44.
WilminkH.W., StroesE.S., ErkelensW.D.Influence of folic acid on postprandial endothelial dysfunction.Arterioscler Thromb Vasc Biol2000; 20: 185–8.
45.
GhiadoniL., MagagnaA., VersariD., KardaszI., HuangY., TaddeiS., SalvettiA.Different effect of antihypertensive drugs on conduit artery endothelial function.Hypertension2003; 41: 1281–6.
46.
DagenaisJ.R., YusufS., BourassaM.G.Effects of ramipril on coronary events in high risk persons: result of the heart outcomes prevention evaluation study.Circulation2001; 104: 522–6.
47.
Scandinavian Simvastatin Survival Study Group.Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study.Lancet1994; 344: 1383–9.
JuonalaM., ViikariJ.S., LaitinenT.Interrelations between brachial endothelial function and carotid intima-media thickness in young adults: the cardiovascular risk in young Finns study.Circulation2004; 110: 2918–23.
